Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab for Postprandial Lipids in Type 2 Diabetes
NCT02948777Phase 4Completed
- Start
- Oct 2016
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of evolocumab in dyslipidemia. Primary endpoints: Mean ApoB Concentration at 12 weeks, Mean TRL-C Concentration at 12 weeks and 3 more. Started Oct 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02948777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948777.